# A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

> **NCT04972968** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 181 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** ABBV-154
- **DRUG:** Placebo
- **DRUG:** Glucocorticoid

## Key facts

- **NCT ID:** NCT04972968
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-09
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-07-24
- **Target enrollment:** 181 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04972968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04972968, "A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04972968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*